← Back to the biomarker database

Hydrochlorothiazid: the pathway in the body

This page shows the biochemical pathway of the active substance Hydrochlorothiazid: where it arrives in the body, where it acts and which steps are affected by that. Every statement has a source. The page describes general textbook knowledge and says nothing about any individual person.

In brief

Hydrochlorothiazide is a thiazide. It acts from the urine side and settles, in the first part of the distal convoluted tubule, on the Na-Cl cotransporter — the protein that reclaims sodium and chloride together from the urine.

What this is about

The kidney filters blood and reclaims from the prefiltered fluid whatever the body is to keep. In the first part of the convoluted tubule it works like this:

Hydrochlorothiazide settles on the NCC and halts its passage. Sodium and chloride are no longer reclaimed together here — the label describes both going into the urine in roughly equal amounts, accompanied by a loss of potassium and bicarbonate. For calcium it runs the other way: with the NCC occupied, a stronger reclaim is described, unlike with loop diuretics. For magnesium and for zinc a greater output into the urine is described.

What this means in an individual case depends on many things and belongs in a conversation with a doctor or health practitioner.

Source 1, 2, 3, 4, 6, 7, 8

14 stations · 9 sources
ORYPath of the substanceAction at the renal tubuleNCCsodiumchlorideNa-K-ATPaseMg-ATPENaCNa-K pumppotassium in exchangeTRPV5, NCX1TRPM6settles at the NCChalts the NCCdescribed with NCC occupieddescribed with NCC occupiedHydrochlorothiazidetablet, swallowedPassage into the bloodfrom the small bowelOn into the urineunchanged, via the kidneyAt the binding siteof the Na-Cl cotransporterSodium and chloridein the tubular fluidInside the tubule cellbrought in by the NCCBack into the bloodvia the sodium-potassium pumpWhat is left overflows on down the tubuleIn the collecting ductsodium via the ENaC channelPotassium into urinehanded over in one moveCalcium in the tubulein through TRPV5More calcium reclaimeddescribed under thiazidesMagnesium at TRPM6channel in the same segmentMagnesium in the urinegreater output described

Swipe the graphic sideways

The pathway step by step

  1. Hydrochlorothiazide → Passage into the blood From the small bowel the substance passes into the blood and reaches the kidney with it. The label states that it is not metabolised in the body. Source 8
  2. Passage into the blood → On into the urine The kidney eliminates the substance rapidly and largely unchanged. It thus reaches the tubule from the inside — from the urine side, where its binding site also lies. Source 8, 1
  3. Sodium and chloride → Inside the tubule cell NCC · sodium, chloride The NCC takes up one sodium and one chloride particle together; both pass only side by side. With hydrochlorothiazide in place, this reclaim does not happen. Source 1, 8
  4. Inside the tubule cell → Back into the blood Na-K-ATPase · Mg-ATP On the side facing the blood, the sodium-potassium pump moves sodium out and potassium in. It splits ATP to do so and holds the gradient that lets the NCC work. Source 5, 1
  5. Sodium and chloride → What is left over What is not reclaimed at the NCC flows on. The label states that the substance sends sodium and chloride into the urine in roughly equal amounts. Source 8, 1
  6. What is left over → In the collecting duct ENaC In the collecting duct sodium enters the cell through the channel ENaC. How much arrives there depends on how much was reclaimed further up. Source 4
  7. In the collecting duct → Potassium into urine Na-K pump · potassium in exchange As sodium enters through ENaC, the cell hands potassium into the urine in the same move. Alongside the sodium output the label names a loss of potassium and bicarbonate. Source 4, 8
  8. Calcium in the tubule → More calcium reclaimed TRPV5, NCX1 With the NCC occupied, a stronger reclaim of calcium is described — unlike with loop diuretics. Two places are named for it: the proximal segment and the convoluted tubule itself. Source 2, 3
  9. Magnesium at TRPM6 → Magnesium in the urine TRPM6 Under thiazides, a smaller amount of TRPM6 in the convoluted tubule and a greater output of magnesium with the urine are described. Source 2, 6

What the kidney handles differently

What takes part in these steps

What the prescribing information states

The prescribing information for this substance comes from an older labelling format. It lists the reported reactions by organ system and gives neither frequencies nor a comparator or placebo group; figures stand there only for the reports after approval. The table repeats what stands there under each heading.

How to read this table: apart from the last row it holds no figures, because the label gives none. Without a comparison group it cannot be said how often a reaction occurs, nor whether it would be rarer without the substance. The figures in the last row are given as additional cases per patients per year, not as a share. The order within a row comes from the label: it starts with the most severe.

What the prescribing information lists there
Body as a wholeWeakness
Heart and circulationPressure in the circulation too low, also on standing up
DigestionPancreatitis, jaundice from bile stasis in the liver, diarrhoea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, loss of appetite
Blood countsAplastic anaemia, agranulocytosis, leucopenia, haemolytic anaemia, thrombocytopenia
HypersensitivityAnaphylactic reactions, necrotising angiitis (vasculitis, also of the skin), respiratory distress including pneumonitis and fluid in the lungs, photosensitivity, fever, urticaria, rash, purpura
MetabolismShift in the salts, raised sugar in the blood, sugar in the urine, raised uric acid
MuscleMuscle spasm
Nervous system and mindVertigo, paraesthesias, dizziness, headache, restlessness
KidneyRenal failure, reduced kidney function, interstitial nephritis
SkinErythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia
SensesTransient blurred vision, xanthopsia
Urinary and genital organsErectile difficulty
After approvalNon-melanoma skin cancer: Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥50,000 mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.

The last row stands in the prescribing information under the heading “Postmarketing Experience”; it reproduces what was evaluated there after approval. The prescribing information closes the section with the sentence that whenever adverse reactions are moderate or severe, the thiazide dose should be reduced or therapy withdrawn.

Sources

  1. Rioux AV, Nsimba-Batomene TR, Slimani S et al. Navigating the multifaceted intricacies of the Na(+)-Cl(-) cotransporter, a highly regulated key effector in the control of hydromineral homeostasis. Physiol Rev 2024 · PubMed 38329422
  2. Alexander RT, Dimke H. Effect of diuretics on renal tubular transport of calcium and magnesium. Am J Physiol Renal Physiol 2017 · PubMed 28274923
  3. Reilly RF, Huang CL. The mechanism of hypocalciuria with NaCl cotransporter inhibition. Nat Rev Nephrol 2011 · PubMed 21947122
  4. Palmer BF. Regulation of Potassium Homeostasis. Clin J Am Soc Nephrol 2015 · PubMed 24721891
  5. Clausen MV, Hilbers F, Poulsen H. The Structure and Function of the Na,K-ATPase Isoforms in Health and Disease. Front Physiol 2017 · PubMed 28634454
  6. Kröse JL, de Baaij JHF. Magnesium biology. Nephrol Dial Transplant 2024 · PubMed 38871680
  7. Braun LA, Rosenfeldt F. Pharmaco-nutrient interactions - a systematic review of zinc and antihypertensive therapy. Int J Clin Pract 2013 · PubMed 23279674
  8. US prescribing information (United States): Hydrochlorothiazide Tablets USP, DailyMed, version of 24 Sept 2026, sections DESCRIPTION, CLINICAL PHARMACOLOGY and Pharmacokinetics and Metabolism · Prescribing information
  9. US prescribing information (United States): Hydrochlorothiazide Tablets USP, DailyMed, version of 24 Sept 2026, section ADVERSE REACTIONS · Prescribing information

As of 2026-09-25. Draft, written by Claude to schema v2; sources checked in PubMed; expert approval pending
Legal notice Privacy policy All biomarkers